RT Journal Article
SR Electronic
T1 Etiological Group Analysis of Cytokine Response To Influenza-Like Illnesses
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.12.16.20248297
DO 10.1101/2020.12.16.20248297
A1 Plotnikova, Marina A.
A1 Klotchenko, Sergey A.
A1 Lozhkov, Alexey A.
A1 Lebedev, Kirill I
A1 Taraskin, Alexander S.
A1 Baranovskaya, Irina L.
A1 Egorova, Maria A
A1 Ramsay, Edward S.
A1 Vasin, Andrey V.
YR 2020
UL http://medrxiv.org/content/early/2020/12/18/2020.12.16.20248297.abstract
AB Respiratory infections, collectively, are one of the world’s most common and serious illness groups. As recent observations have shown, the most severe courses of acute respiratory infection, often leading to death, are due to uncontrolled cytokine production (hypercytokinemia). The research presented is devoted to assessment of mRNA expression of specific cytokines (IL-1b, IL-2, IL-4, IL-6, IL-8, IL-10, IL-18, TNF-α, IFN-λ) and MxA in whole blood leukocytes, by means of real-time PCR. This study involved 364 patients with respiratory illness being treated in clinics in St. Petersburg (Russia) in 2018-2019 and 30 healthy subjects. In 70% of patients, bacterial or viral pathogens were identified, with influenza viral infections (types A, B) prevailing. Cytokine analysis was carried out in the acute phase of illness (2-3 days from onset of initial symptoms) and in the stage of recovery (days 9-10). Significant increases in the expression of IL-18, TNF, and IL-10 were observed, relative to controls, only with influenza viral infections. We have shown a difference in IL-6 mRNA expression in patients with bacterial or viral pathogens. No significant difference was found in WBC IL-4 expression levels between patients and healthy subjects. Investigation of the nuances of systemic cytokine production, in response to specific viral and bacterial pathogens, makes it possible to: assess the risks of developing hypercytokinemia during respiratory infection with agents circulating in the human population; and to predict the pathogenicity and virulence of circulating threats.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialSmorodintsev Research Institute of Influenza institutional Ethics Committee (protocol No. 108, dated September 03, 2018)Funding StatementThis research work was supported by a Russian State Assignment for Fundamental Research, 0784-2020-0023.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study and its protocols were approved by the Smorodintsev Research Institute of Influenza institutional Ethics Committee (protocol No. 108, dated September 03, 2018).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesInformed consent was obtained from all donors and patients who provided research materials.IVAinfluenza A virus(es)IVBinfluenza B virus(es)RSVhuman orthopneumovirus(es)HMPVhuman Metapneumovirus(es)HPIVhuman parainfluenza virus(es)HCoVhuman Coronavirus(es)HRVhuman Rhinovirus(es)HAdVhuman Adenovirus(es)